Ìô¡¦¼£ÎŤˤĤ¤¤ÆÃÎ¤í¤¦

Æý¤¬¤ó¡ÃÆý¤¬¤óͽËɤϻ׽մü¤«¤é

¥­¡¼¥ï¡¼¥É¡¡Æý¤¬¤ó¡¡ÆÍÁ³ÊÑ°Û¡¡²Ìʪ

 

ÏÀʸ£±¡¡Evolutionary histories of breast cancer and related clones

»×½Õ´ü¤Ë²Ìʪ¤ò¤¿¤¯¤µ¤ó¿©¤Ù¤Æ¤¤¤¿¿Í¤Ï¤½¤¦¤Ç¤Ê¤«¤Ã¤¿¿Í¤è¤ê¤âÆý¤¬¤ó¥ê¥¹¥¯¤¬25¡ó¤âÄ㤤

¤È¤¤¤¦¥Ï¡¼¥Ð¡¼¥ÉÂç³Ø¤¬¼Â»Ü¤·¤¿±Ö³Ø¸¦µæ·ë²Ì¤¬¤¢¤ê¤Þ¤¹¡£

¡üÌó£¹Ëü¿Í¤òÂоݤˤ·¤¿¸¦µæ

¡üÂç¿Í¤Ë¤Ê¤Ã¤Æ¤«¤é¤Î²Ìʪ¤ÎÀݼèÎ̤ÈÆý¤¬¤ó¥ê¥¹¥¯¤òÈæ³Ó¤·¤¿¾ì¹ç¤Ï¡¢¥ê¥¹¥¯¤Ëº¹¤¬¤Ê¤«¤Ã¤¿¡£

¡ü¡Ö»×½Õ´ü¡×¤Ë»þ´ü¤ò¹Ê¤Ã¤¿·ë²Ì¡¢Æý¤¬¤ó¥ê¥¹¥¯¤È»×½Õ´üº¢¤Î²ÌʪÀݼèÎ̤ȴØÏ¢¤¬Ç§¤á¤é¤ì¤¿¡£

 

 

¤³¤Î¤è¤¦¤Ë¿¤¯¤Î¿Í¤òÄÉÀפ·¤¿±Ö³Ø¸¦µæ¤Ï¤«¤Ê¤êÂç»ö¤ÊÌò³ä¤ò²Ì¤¿¤·¤Æ¤¤¤Þ¤¹¡£

¤½¤ì¤Ï¡¢Éµ¤¤Î¥ê¥¹¥¯¤ä¿©¤Ùʪ¤Î¸ú²Ì¤Ê¤É¤ò¸¡¾Ú¤¹¤ë¤Ë¤Ï¡¢

¿¤¯¤Î¿Í¤òÂоݤˤ·¤Æ¡¢¤½¤ì¤¾¤ì¤Î¿Í¤ÎÀ¸³è¥¹¥¿¥¤¥ë¤Î°ã¤¤¤òÊäÀµ¤·¤¿Ãͤˤ·¤Æ¡¢

¿§¤ó¤ÊÍ×°ø¤ÈÈæ³Ó¤¹¤ë¤³¤È¤¬É¬ÍפÀ¤«¤é¤Ç¤¹¡£

¤³¤Î¸¦µæ¤â¡¢Âç¿Í¤Îº¢¤Î²ÌʪÀݼè¤ÈÆý¤¬¤ó¥ê¥¹¥¯¤Ëº¹¤¬Ç§¤á¤é¤ì¤Ê¤«¤Ã¤¿¤Î¤Ç¤¹¤¬¡¢

»×½Õ´ü»þ¤Î²ÌʪÀݼèÎ̤ǥ°¥ë¡¼¥×ʬ¤±¤·¤¿¤é¡¢Æý¤¬¤ó¥ê¥¹¥¯¤Ëº¹¤¬É½¤ì¤Þ¤·¤¿¡£

±Ö³Ø¸¦µæ¤ÇÌÀ¤é¤«¤Êº¹¤¬Ç§¤á¤é¤ì¤¿¤â¤Î¤ò¡¢¤Þ¤ºµ¤¤Ë¤·¤Æ¤ß¤Æ¤Ï¤É¤¦¤Ç¤·¤ç¤¦¤«¡£

 

ÏÀʸ£²

µþÅÔÂç³Ø¡¢Åìµþ°å²Ê»õ²ÊÂç³Ø¡¢·ÄØæµÁ½ÎÂç³Ø¤Î¶¦Æ±¸¦µæ2023ǯ£··îȯɽ

Æý¤¬¤ó´µ¼Ô¤ÎºÙ˦¤ò¸¦µæ¤·¤¿¤é¡¢¤¢¤ë°äÅÁ»ÒÊѲ½¡ÊÆý¤¬¤ó¤Î20¡óÁêÅö¡Ë¤Ï»×½Õ´ü¤Ëµ¯¤­¤Æ¤¤¤¿¤³¤È¤¬Ê¬¤«¤Ã¤¿

¤³¤ì¤ÏÆý¤¬¤óÁ´¤Æ¤ò²òÌÀ¤·¤¿·ë²Ì¤Ç¤Ï¤Ê¤¯¡¢Æý¤¬¤ó¤Î¿§¡¹¤Ê¥Ñ¥¿¡¼¥ó¤ÎÃæ¤Ç¡¢¤¢¤ë°äÅÁ»ÒÊѲ½¤Î´µ¼Ô¤ÎºÙ˦¤ÎÎò»Ë¤òÄ´¤Ù¤¿¸¦µæ¤Ç¤¹¡£Â¾¤ÎÆý¤¬¤ó¤âÄ´¤Ù¤¿¤éƱ¤¸¤è¤¦¤Ê·ë²Ì¤«¤â¤·¤ì¤Ê¤¤¤·¡¢¤½¤¦¤Ç¤Ï¤Ê¤¤¤«¤â¤·¤ì¤Þ¤»¤ó¡£

¡ü»×½Õ´ü¤ÏÆý˼¤¬È¯Ã£¤¹¤ë»þ´ü¤Ç°ìÈÖºÙ˦ʬÎö¤¬À¹¤ó¤Ç¡¢ÆÍÁ³ÊÑ°Û¤¬µ¯¤­¤ë¥ê¥¹¥¯¤Ï¹â¤¤»þ´ü

¡üÆÍÁ³ÊÑ°Û¤ÏËèǯ1¤Ä¤ÎºÙ˦¤Ë20¸Ä¤º¤Ä¤Ç¤­¤Æ¤¤¤¿¡ÊÆÍÁ³ÊѰۤϤ¹¤Ù¤Æ´â¤Ë¤Ê¤ë¤ï¤±¤Ç¤Ï¤Ê¤¤¡Ë

¡üÆý¤¬¤óÁ´ÂΤÎÌó20%¤òÀê¤á¤ë¡Öder(1;16)žºÂÍÛÀ­¤ÎÆý¤¬¤ó¡×¤Î´µ¼Ô¤ÎºÙ˦¤Îµ¯¸»¤òÄ´¤Ù¤ë¤È¤É¤Î´µ¼Ô¤â»×½Õ´üº¢¤Ëµ¯¸»¤¬¤¢¤Ã¤¿

https://www.tmd.ac.jp/press-release/20230727-1/

 

ÏÀʸ£±¤È£²¤«¤é¸À¤¨¤ë¤³¤È¤Ï

ÆÍÁ³ÊѰۤϾï¤ËÂΤˤ¿¤¯¤µ¤ó¤¢¤Ã¤Æ¡¢µÙ̲¤·¤Æ¤¤¤ë¾õÂ֤Ǥ¢¤ë¤³¤È

ÆÍÁ³ÊÑ°Û¤ò¥¬¥ó²½¤µ¤»¤ë¤Î¤Ï¡¢ÌȱֺÙ˦¤ÈÌ©Àܤ˴ط¸¤¬¤¢¤ë¤³¤È

ÌȱֺÙ˦¤¬Ë½Áö¤¹¤ë¡Ê±ê¾É¡Ë¤ò°ú¤­µ¯¤³¤µ¤Ê¤¤¤³¤È¡¢

±ê¾É¤¬µ¯¤­¤Æ¤â±ê¾É¤òÍÞ¤¨¤ëƯ¤­¤ò¤¹¤ëÌîºÚ¤ä²Ìʪ¡¢µû¡Ên-3·Ï»éËûÀ¡Ë¤òÀݤ뤳¤È

 

°Ê²¼¡¢²òÀâµ­»ö

­¡¥¬¥ó¤ÏºÙ˦ʬÎö¤Î¥¢¥¯¥»¥ë¤Î°äÅÁ»Ò(¥É¥é¥¤¥Ð¡¼°äÅÁ»Ò¡á¥¬¥ó°äÅÁ»Ò)¤«ºÙ˦ʬÎö¤ÎÍÞÀ©°äÅÁ»Ò¤ÎξÊý¤¢¤ë¤¤¤Ï¤É¤Á¤é¤«¤¬ÊÑ°Û¤·¤ÆÀ¸¤¸¤ë¤È¹Í¤¨¤é¤ì¤Æ¤­¤Þ¤·¤¿¡£

­¢1¸Ä¤ÎºÙ˦¤Î°äÅÁ»Ò¤ò²òÀϤ¹¤ëµ»½Ñ¤¬¿ÊÊ⤷¡¢Â¬Äꤹ¤ë¤È¡¢¼ÂºÝ¤Ë¤Ï¥¬¥ó°äÅÁ»Ò(¥É¥é¥¤¥Ð¡¼°äÅÁ»Ò)¤¬ÊÑ°Û¤·¤Æ¤¤¤ëºÙ˦¤¬ÁÈ¿¥¤ÎÂçÉôʬ¤òÀê¤á¤Æ¤¤¤ë¤³¤È¤¬ºÇ¶áʬ¤«¤Ã¤Æ¤­¤Þ¤·¤¿¡£¤½¤ì¤é¤ÎºÙ˦¤Ïµ¡Ç½Åª¤Ë¤â·ÁÂÖŪ¤Ë¤âÀµ¾ïºÙ˦¤È¶èÊ̤Ǥ­¤º¡¢ÊѰۤϤ¢¤ë¤â¤Î¤Î¡¢µÙ̲¾õÂ֤ˤ¢¤ë¤È¹Í¤¨¤é¤ì¤Æ¤¤¤Þ¤¹¡£¥¬¥ó²½¤¹¤ë¤Ë¤Ï²¿¤é¤«¤Î(¤­¤Ã¤«¤±)ºîÍѤ¬É¬Íפȹͤ¨¤é¤ì¤Æ¤¤¤Æ¡¢Ê¬»ÒÀ¸Êª³Ø¤ÎºÇ¹âÊö¡¦¥¤¥®¥ê¥¹¤Î¥¯¥ê¥Ã¥¯¸¦µæ½ê¤Î¸¦µæ¤Ç¤Ï¡¢ÌȱֺÙ˦¤Î´ØÍ¿¤¬¾ÚÌÀ¤µ¤ì¤Æ¡¢¤½¤ÎÌȱֺÙ˦¤ÎºîÍÑ(±ê¾É)¤òÍÞ¤¨¤ë¤È¥¬¥ó²½¤¬µ¯¤­¤Þ¤»¤ó¤Ç¤·¤¿¡£

­£ÌȱֺÙ˦¤ÏÄ̾復¥¤¥ë¥¹¡¢ºÙ¶Ý¡¢¥±¥¬(ÁÈ¿¥¤Î½ý³²) ¤Ê¤É¤Î´¶À÷¤¬µ¯¤­¤¿¤È¤­¤ËÁý¿£¤·¡¢¡Ö±ê¾É¡×¤È¤¤¤¦¾õÂÖ¤ò¤Ä¤¯¤ê½Ð¤·¤Þ¤¹¡£¡Ö±ê¾É¡×¤È¤ÏÌȱֺÙ˦¤¬¥¤¥ó¥¿¡¼¥í¥¤¥­¥ó1β(¥Ù¡¼¥¿¡¼)¤Ê¤É¥Û¥ë¥â¥ó¤Î¤è¤¦¤Êʪ¼Á¤ä³èÀ­»ÀÁǤʤɤòÊü½Ð¤·¡¢³°Å¨¤ÈÀ臘¤³¤È¤Ç¤¹¡£¤·¤«¤·ºÇ¶á¡¢¤³¤Î¡Ö±ê¾É¡×¤¬Â絤±øÀ÷¡¢¥È¥é¥ó¥¹»éËûÀ¡¢¥³¥ì¥¹¥Æ¥í¡¼¥ë¡¢Ç¢»À¤Ê¤É¤ËÂФ·¤Æ¤âµ¯¤­¤ë¤³¤È¤¬¤ï¤«¤Ã¤Æ¤­¤Þ¤·¤¿¡£ÌȱֺÙ˦¤Î²á¾êÈ¿±þ¤È¸À¤¨¤Þ¤¹¡£

 

­¢¤Î¥¯¥ê¥Ã¥¯¸¦µæ½ê¤Î¥¬¥ó²½¤Î¤Ò¤­¤¬¤Í¤Ë¤Ê¤Ã¤Æ¤¤¤ëÌȱֺÙ˦¤Î±ê¾É¤Ë¤«¤«¤ï¤Ã¤Æ¤¤¤ëʪ¼Á¤Ï­£¤Ç½ñ¤¤¤¿¥¤¥ó¥¿¡¼¥í¥¤¥­¥óβ¥Ù¡¼¥¿¡¼¤À¤Èʬ¤«¤Ã¤Æ¤¤¤Þ¤¹¡£

¥¤¥ó¥¿¡¼¥í¥¤¥­¥óβ¥Ù¡¼¥¿¡¼¤òÁ˳²¤¹¤ëÌô¥«¥Ê¥­¥Ì¥Þ¥Ö¤òÆ°Ì®¹Å²½¤Î´µ¼Ô¡¢¿Í¤Ëǯ´ÖÅêÍ¿¤·¤¿¤È¤³¤í¡¢ÅêÍ¿¤·¤¿´µ¼Ô¤Ç¤Ï¡¢ÇÙ¥¬¥ó¤òȯ¾É¤¹¤ë´µ¼Ô¤¬¤â¸º¾¯¤·¤¿¡£¤¬¡£Áí»à˴Ψ¤Ï´¶À÷¾É»à¤ÎÁý²Ã¤Ë¤è¤Ã¤ÆÊѤï¤é¤Ê¤¤·ë²Ì¤Ë¤Ê¤ê¤Þ¤·¤¿¡£¤Ä¤Þ¤ê¡¢ÇÙ¥¬¥ó¤Ë¤Ï¤«¤«¤é¤º¤È¤âÌȱÖÎϤÎÄã²¼¤ò¾·¤¤¤Æ¤¤¤ë²ÄǽÀ­¤¬¤¢¤ë¡£

 

ºÙ˦¤Î¥¬¥ó²½¤Î°ú¤­¶â¤Ë¤Ê¤Ã¤Æ¤¤¤ë±ê¾É¤ò»ß¤á¤ë¤¿¤á¤Ë¤Ï¡¢Ìô¤ËÍê¤é¤º¡¢°­¤¤±Æ¶Á¤¬½Ð¤Ë¤¯¤¤¿©ÉʤʤɤËÍê¤ëɬÍפ¬¤¢¤ê¤Þ¤¹¡£

¥Ý¥ê¥Õ¥§¥Î¡¼¥ë¡¢¿©ÊªÁ¡°Ý¡¢n-3·Ï»éËûÀ¤Ê¤É¤¬±ê¾É¤òÍÞ¤¨¤ë»ö¤¬Ê¬¤«¤Ã¤Æ¤¤¤Þ¤¹¡£

 

¤³¤ì¤é¤Î·ëÏÀ¤Ï³Ú´ÑÏÀ¤Î¸¶°ø¤È¤Ê¤ë¡¨¤Ê¤¼¤Ê¤é»ä¤¿¤Á¤Ï¥¬¥ó¤Î¥ê¥¹¥¯¤òÁý¤ä¤¹°äÅÁ»ÒÍ×°ø¤òÊѤ¨¤ë¤³¤È¤Ï¤Ç¤­¤Ê¤¤¤¬¡¢¤¿¤¯¤µ¤ó¤ÎÌîºÚ¤ò´Þ¤àŬÀڤʿ©»ö¤ò¤È¤ë¤³¤È¤Ë¤è¤Ã¤Æ¡¢¤ª¤½¤é¤¯¥¬¥ó¤Î¥ê¥¹¥¯¤ò¸º¤é¤¹¤³¤È¤¬¤Ç¤­¤ë¡£(2018ǯ ¥¯¥ê¥Ã¥¯¸¦µæ½ê)

 

¡Ê¤Þ¤È¤á¡§Æ⻳¡Ë

 

´ØÏ¢µ­»ö

http://1.nagoyaseikatsuclub.com/?eid=201

 

 

 

ÅüǢɡ÷ìÅüÃͤοä°Ü¤Ï¿Í¤½¤ì¤¾¤ì

¥­¡¼¥ï¡¼¥É

ÅüǢɠ·ìÅüÃÍ ·ìÅüÃÍ¥¹¥Ñ¥¤¥¯

 

Ʊ¤¸¿©À¸³è¤ò¤·¤Æ¤¤¤Æ¤â¡¢¤ä¤»¤ë¿Í¡¢ÂÀ¤ë¿Í¡¢ÅüǢɤˤʤë¿Í¡¢¤Ê¤é¤Ê¤¤¿Í¤¬¤¤¤ë¤Î¤Ï¤É¤¦¤·¤Æ¤Ê¤Î¤Ç¤·¤ç¤¦¤«¡£
¤½¤ì¤Ï¡¢¸¶°ø°ø»Ò¤¬¿©¤À¤±¤Ç¤Ï¤Ê¤¤¤«¤é¤Ç¤¹¡£
IJÆâºÙ¶ÝÁѤâ²È²¤ÎÃæ¤Ç¤â°ã¤¤¤Þ¤¹¡£
°Ê²¼¤ÎÏÀʸ¤Ï¡¢ÍÍ¡¹¤ÊÍ×°ø¤«¤é¡¢ÅüÇ¢É¤δµ¼Ô¤¬¤É¤ó¤Ê¿©»ö¡¦À¸³è¤ò¤¹¤ì¤Ð·ìÅüÃͤξ徺¤¬´Ë¤ä¤«¤Ë¤Ê¤ë¤«Í½Â¬²Äǽ¤Ë¤Ê¤Ã¤¿¤È¤¤¤¦ÆâÍƤǤ¹¡£ÅüǢɤò²þÁ±¤¹¤ë¾å¤Ç¤³¤ÎÊýË¡¤¬ÆüËܤǤâ¼è¤êÆþ¤ì¤ë¤è¤¦¤Ë¤Ê¤Ã¤¿¤é¡¢³×¿·Åª¤Ê¤³¤È¤Ç¤¹¡£

¡²¡²¡²¡²¡²¡²¡²¡²¡²¡²¡²¡²¡²¡²¡²¡²¡²¡²¡²¡²¡²¡²¡²¡²¡²¡²¡²¡²¡²¡²

Personalized Nutrition by Prediction of Glycemic Responses.
·ìÅüÈ¿±þ¤ÎͽÁۤˤè¤ë¸Ä¿ÍÊ̱ÉÍÜ
David Zeevi ¡¡¥ï¥¤¥Ä¥Þ¥ó¸¦µæ½ê¡¡¥¤¥¹¥é¥¨¥ë
Cell 163,1079-1094,November 19.2015

 

¿©¸å¡¢·ìÅüÃ;徺¤Ï¡¢Á°ÅüǢɡ¢­¶·¿ÅüÇ¢ÉÂ¤Ê¤É¤Î´í¸±°ø»Ò¤Ç¤¢¤ê¡¢º£¤Þ¤Ç¤Î¿©»ö»ØƳ¤Ï¸ú²Ì¤¬¸ÂÄêŪ¤Ç¤¹¡£»ä¤¿¤Á¤Ï800¿Í¤Î·ìÅüÃͤò1½µ´ÖϢ³Ū¤Ë¬Äꤷ¡¢46898¿©¤Ø¤ÎÈ¿±þ¤òÄ´¤Ù¤¿¡£Æ±°ì¤Î¿©»ö¤ËÂФ·¤Æ¤â¸Ä¿Í´Ö¤Î°ã¤¤¤¬Â礭¤¯¡¢¸½ºß¤Î°ìÈÌŪ±ÉÍÜ»ØƳ¤¬¤¢¤Þ¤ê¸ú²Ì¤¬¤Ê¤¤¤³¤È¤ò¼¨¤·¤Æ¤¤¤Þ¤¹¡£
»ä¤¿¤Á¤Ï·ì±Õ¤Î¬ÄêÃÍ¡¢¿©½¬´·¡¢¿ÍÂοôÃÍ¡¢±¿Æ°ÎÌ¡¢Ä²ÆâºÙ¶Ý¤Î³Æ¿ôÃͤòÅý¹ç¤·¡¢¿©¸å·ìÅüÃͤò¼ÂÀ¸³è¤Î¿©»ö¤ÇÀµ³Î¤Ëͽ¬¤Ç¤­¤ë¤³¤È¤ò¼¨¤·¤¿¡£
¤³¤ÎÊýË¡¤òÆó½ÅÌÕ¸¡¤Ç¼ÂºÝ¤Ë»î¤·¤¿¤È¤³¤í¡¢Í½Â¬Ä̤ꡢ¿©¸å·ìÅüÃͤÏÄ㤯¡¢¤½¤ì¤Ë½¾¤Ã¤ÆIJÆâºÙ¶Ý¤âÊѲ½¤·¤¿¡£

¾åµ­¥°¥é¥Õ¤Ï4¿Í¤ÇÈæ³Ó¤·¤¿¡¢¥Ñ¥ó¤ò¿©¤Ù¤¿¸å¤Î·ìÅüÃÍ¿ä°Ü¤Ç¤¹¤¬¡¢¿Í¤Ë¤è¤Ã¤Æ·ìÅüÃͤοä°Ü¤¬°Û¤Ê¤ë¤³¤È¤¬Ê¬¤«¤ê¤Þ¤¹¡£

 

¾åµ­¥°¥é¥Õ¤Ï´µ¼ÔE3¤Î¿Í¤¬¤¤¤¤¿©À¸³è¤È°­¤¤¿©À¸³è¤ò1½µ´Ö¤º¤Ä²á¤´¤·¤¿ºÝ¤Î¡¢·ìÅüÃͤοä°Ü¤ÈIJÆâºÙ¶Ý¤Î¿ä°Ü¡£
¡ü¤¤¤¤¿©À¸³è¤ò¤·¤Æ¤¤¤ë´Ö
²«¿§¤ÎÀþ¤ÎÁ±¶Ì¶Ý¤¬Áý²Ã¡¢·ìÅüÃÍ¿ä°Ü¤¬¤ª¤À¤ä¤«
¡ü°­¤¤¿©À¸³è¤ò¤·¤Æ¤¤¤ë´Ö
²«¿§¤ÎÀþ¤ÎÁ±¶Ì¶Ý¤¬¸º¾¯¡¢·ìÅüÃÍ¿ä°Ü¤¬·ã¤·¤¤

¤È¤¤¤¦¤³¤È¤¬Ê¬¤«¤ê¤Þ¤¹¡£

 

¿©À¸³è¤ò¿ôÆü¤«¤¨¤ë¤À¤±¤Ç¤â¡¢Á±¶Ì¶Ý¤¬Í¥°Ì¤ËÆþ¤ìÂؤï¤ëÍͻҤ¬¤è¤¯Ê¬¤«¤ê¤Þ¤¹¤Í¡£

¡²¡²¡²¡²¡²¡²¡²¡²¡²¡²¡²¡²¡²¡²¡²¡²¡²¡²¡²¡²¡²¡²¡²¡²¡²¡²¡²¡²¡²¡²¡²¡²¡²¡²¡²¡²

½ñ¤¤¤Æ¤¤¤ë»ä¤â·ìÅüÃÍ¥¹¥Ñ¥¤¥¯¤Î¾É¾õ¤¬¸½¤ì¤ë¤³¤È¤¬¤¢¤ê¤Þ¤¹¡£

ÅüÇ¢ÉÂͽÈ÷·³¡ª¡©¤Ã¤Æ»×¤Ã¤Æ¡¢Çþ¤´ÈÓ¤ËÀÚ¤êÂؤ¨¤¿¤ê¡¢¥Ñ¥ó¤ò¾Æ¤¯¤È¤­¤ÏÁ´Î³Ê´¤ò»È¤Ã¤¿¤ê

¤·¤Æ¤¤¤Þ¤¹¤¬¡¢¤Þ¤À¤Þ¤À¿©ÊªÁ¡°Ý¤¬Â­¤ê¤Ê¤¤¤Î¤«¤Ê¤È»×¤Ã¤Æ¤¤¤Þ¤¹¡£

ÌîºÚ→¥¿¥ó¥Ñ¥¯¼Á→Åü¼Á¤Î½ç¤Ç¿©¤Ù¤ë¤Î¤¬ÍýÁۤǤ¹¤¬¡¢

Ä«¤¬¤Ê¤«¤Ê¤«Ã£À®¤Ç¤­¤Ê¤¤¡¦¡¦¡¦¡£¤Ç¤âËÜÅö¤ÏÄ«¿©¤³¤½·ìÅüÃÍ´ÉÍý¤Î¾å¤Ç¤ÏÂç»ö¤Ê¤ó¤Ç¤¹¤è¤Í¡£

Ä«¿©¤ËÇþ¤´ÈÓ¤ò¿©¤Ù¤ë¤È¡¢Ãë¿©¡¦Í¼¿©¤Î·ìÅüÃͤξ徺¤¬´Ë¤ä¤«¤Ë¤Ê¤ë¤³¤È¤Ïʬ¤«¤Ã¤Æ¤¤¤ë¤ó¤Ç¤¹¡£

·ìÅüÃͤ¬µ¤¤Ë¤Ê¤Ã¤Æ¤¤¤ëÊý¤Î»²¹Í¤Ë¤Ê¤ì¤Ð¹¬¤¤¤Ç¤¹¡£¡ÊÆ⻳¡Ë

 

ƬÄËÌô¤ÎÍðÍѤËÃí°Õ

 

ƬÄËÌô¤òÍðÍѤ¹¤ë¤ÈÆñÄ°¤Î¥ê¥¹¥¯¤¬¹â¤Þ¤ê¤Þ¤¹¡£

ƬÄˤÏÉî¤é¤º¡¢É±¡¤Ç¸¶°ø¤òõ¤·¤Æ¤ß¤ë¤Î¤¬¤¤¤¤¤«¤â¤·¤ì¤Þ¤»¤ó¡£

 

 

Nurses’ Health Study links over-the-counter medication for pain relief with hearing loss.

Ìô¶É¤Ç¤ÎƬÄËÌô¤¬ÆñÄ°¤Ë¤Ä¤Ê¤¬¤ë

 

NSAIDs(Èó¥¹¥Æ¥í¥¤¥É·Ï¹³±ê¾ÉÌôŽ¥Ž¥Ž¥¥¢¥¹¥Ô¥ê¥ó¡¢¥µ¥ê¥Á¥ë»À¡¢¥¤¥Ö¥×¥í¥Õ¥§¥ó¡¢¥Ý¥ë¥¿¥ì¥ó¡¢¥¤¥ó¥É¥á¥¿¥·¥ó¡¢¥Ê¥×¥í¥­¥»¥ó¤Ê¤É)¤È¥¢¥»¥È¥¢¥ß¥Î¥Õ¥§¥ó¡Ê¥Î¡¼¥·¥ó¤Ê¤É¡Ë

NHS»²²Ã¼Ô5Ëü5000¿Í¤òÄÉÀפ·¡¢¥¤¥Ö¥×¥í¥Õ¥§¥ó¤Ê¤É¤ÈNSAIDsÌô¤ä¥¢¥»¥È¥¢¥ß¥Î¥Õ¥§¥ó¤ò¤è¤¯6ǯ°Ê¾å»È¤Ã¤Æ¤¤¤ë¿Í¤Ï¡¢ÆñÄ°¤Î¥ê¥¹¥¯¤¬9¡ó¤«¤é10¡ó¾å¤¬¤ë¡£

¥Õ¥§¥ó¥Í¥ë¥Æ¥£¡¼¤Î¥ê¥¹¥¯¥¢¥»¥¹¥á¥ó¥È

ÏÀʸ¤Ç¾Ò²ð¤·¤Þ¤¹

Fennel tea risk assessment of the phytogenic monosubstance estragole in comparison to the natural multicomponent mixture
¥Õ¥§¥ó¥Í¥ë¥Æ¥£¡¼¤Î¥ê¥¹¥¯¥¢¥»¥¹¥á¥ó¥È¡Ê¼«Á³¤Ê¿À®Ê¬¤Êº®¹çʪ¤È¿¢ÊªÍ³Íè¤Îñ°ìʪ¼Á¡Ý¡Ê¥¨¥¹¥È¥é¥´¡¼¥ë¡Ë¡Ý¤ÈÈæ³Ó¤·¤Æ¡Ë
Iten F ¥·¥å¥Ô¥¿¡¼¥ë¡©Âç³Ø¡¡¥¹¥¤¥¹
Forsch komplementarmed klass Naturheikd 2004 Apr 11(2) 104-8


²¿À¤µª¤â¤Î´Ö¡¢¥Õ¥§¥ó¥Í¥ë¤Ï¡¢ÅÁÅýŪ¤Ê¥Ï¡¼¥Ö¼£ÎÅÌô¤È¤·¤Æ¡¢¥è¡¼¥í¥Ã¥Ñ¤ÈÃæ¹ñ¤Ç»È¤ï¤ì¤Æ¤­¤¿¡£¾Ã²½ÉÔÎɤòµ¯¤³¤·¤Æ¤¤¤ëÍÄ»ù¤ÈÆý»ù¤Î¼£ÎŤˡ¢¥Õ¥§¥ó¥Í¥ë¥Æ¥£¡¼¤Ï¡¢ºÇ½é¤ÎÁªÂò¤Ç¤¹¡£

¤³¤ÎŤ¯»Ù»ý¤µ¤ì¤Æ¤­¤¿·Ð¸³¤¬¡¢¶Ã¤¯¤³¤È¤Ë¡¢¥É¥¤¥ÄϢˮÀ¯ÉܤΡ©À¼ÌÀ¤ÇÂоÈŪ¤Ë¤Ê¤Ã¤¿¡£

¤½¤ì¤Ï¡¢¥¨¥¹¥È¥é¥´¡¼¥ë¡¢¥á¥Á¥ë¥æ¡¼¥²¥Î¡¼¥ë¤Ê¤É¤ò´Þ¤à¿©ÉÊÀݼè¤ò¸º¤é¤¹Íͤ˾ÃÈñ¼Ô¤Ëµá¤á¤¿À¼ÌÀ¤Ç¤·¤¿¡£¥¿¥é¥´¥ó¡¢¥Ð¥¸¥ë¡¢¥¢¥Ë¥¹¡¢¥¹¥¿¡¼¥¢¥Ë¥¹¡¢¥¸¥ã¥Þ¥¤¥«¥Ú¥Ã¥Ñ¡¼¡¢¥Ê¥Ä¥á¥°¡¢¥ì¥â¥ó¥°¥é¥¹¡¢¥Ó¥¿¡¼¥Õ¥§¥ó¥Í¥ë¡¢¥¹¥¦¥£¡¼¥È¥Õ¥§¥ó¥Í¥ë¤Ê¤É¤Ç¤¹¡£

¤³¤ì¤é¤Î·Ù¹ð¤Ï¡¢¥Õ¥§¥ó¥Í¥ëÃæ¤ÎÀ®Ê¬¡¢¥¨¥¹¥È¥é¥´¡¼¥ë¤¬¥é¥Ã¥È¤È¥Þ¥¦¥¹¤òȯ¥¬¥ó¤µ¤»¤ë¡¢¤È¤¤¤¦¼Â¸³¤Ë´ð¤Å¤¤¤Æ¤¤¤Þ¤¹¡£

¤·¤Ð¤é¤¯¤·¤Æ¡¢ÈãȽ¤¬ÀìÌç²È¤«¤éµ¯¤³¤ê¤Þ¤·¤¿¡£ÈãȽ¤Ï¡¢Ã±°ì¤Îʪ¼Á¡Ê¥¨¥¹¥È¥é¥´¡¼¥ë¡Ë¤ò¹âÍÑÎ̤ÇÍ¿¤¨¤Æ¤¤¤ëÅÀ¤Ç¡¢¤½¤ì¤Ï¡¢¥Ò¥È¤Î¾ÃÈñÎ̤ËÁ´Á³¸«¹ç¤Ã¤Æ¤¤¤Ê¤¤¡¢¤È¤¤¤¦½ê¤Ç¤¹¡£

¤µ¤é¤Ë¡¢¥Ò¥È¤È¡¢¥Þ¥¦¥¹¤Ç¤Ï¥¨¥¹¥È¥é¥´¡¼¥ë¤ÎÂå¼Õ¤ËÎÌŪ¤ÊÁê°ã¤¬¤¢¤ë¤È¤¤¤¦¤³¤È¤ò¸¦µæ¤¬ÌÀ¤é¤«¤Ë¤·¤Þ¤·¤¿¡£

¤µ¤é¤Ë¡¢£±¤Ä¤Îʪ¼Á¤¬Ã±°ì¤Îʪ¼Á¤È¤·¤ÆÅêÍ¿¤µ¤ì¤ë»þ¤È¡¢Å·Á³¤ÎÊ£»¨¤ÊÀ®Ê¬¤Î£±¤Ä¤È¤·¤ÆÅêÍ¿¤µ¤ì¤ë»þ¤Ç¤Ï¡¢ÉûºîÍѤ¬Á´Á³°Û¤Ê¤Ã¤Æ¤¤¤ë¡¢¤È¤¤¤¦¤³¤È¤â¼¨¤µ¤ì¤Þ¤·¤¿¡£

¤³¤ÎÍͤˡ¢¥Õ¥§¥ó¥Í¥ë¥Æ¥£¡¼¤ÎÍͤˡ¢¤¤¤í¤¤¤í¤ÊÀ®Ê¬¤Îº®¤¸¤ê¤¢¤Ã¤¿Êª¤Ï¡¢¥¬¥ó¤òͽËɤ¹¤ë¡¢¼ï¡¹¤Î»À²½Ëɻߺޤò´Þ¤ó¤Ç¤¤¤Þ¤¹¡£

¤³¤ì¤é¤Î°ã¤¤¤Ï¡¢¥ê¥¹¥¯¥¢¥»¥¹¥á¥ó¥È¤Çɾ²Á¤µ¤ì¤Þ¤»¤ó¡£

¤è¤¤¥ê¥¹¥¯¥¢¥»¥¹¥á¥ó¥È¤Ï¡¢¥Ò¥È¤Ç½¸¤á¤é¤ì¤¿Å¬Àڤʥǡ¼¥¿¡¼¤Ë´ð¤Å¤«¤ì¤ë¤Ù¤­¤Ç¤¹¡£

¥Õ¥§¥ó¥Í¥ë¥Æ¥£¡¼¤ÎŤ¤ÅÁÅýŪ¤Ê»ÈÍѤÈȯ¥¬¥óÀ­¤ò¼¨¤¹¡¢±Ö³ØµÚ¤ÓÎ×¾²¸¦µæ¤¬¤Ê¤¤¤Î¤À¤«¤é¡¢¥Õ¥§¥ó¥Í¥ë¥Æ¥£¡¼¤Î¾Ã²½¤Ë´Ø¤·¤Æ¤Î½ÅÂç¤Ê´í¸±À­¤Î³ÎΨ¤Ï¾®¤µ¤¤Íͤ˻פ¦¡£

¡Ê2007/5/7 ·ÇºÜ¡Ë

¼¡¤ÎÆü¤ÎÀä¿©¤ÏÏ·²½¤òÍÞ¤¨¤ë

ÏÀʸ¤Ç¾Ò²ð¤·¤Þ¤¹

Intermittent fasting dissociates beneficial effects of dietary restriction on glucose metabolism and neuronal resistance to injury from calorie intake
¼¡¤ÎÆü¤ÎÀä¿©¤Ï¥Ö¥É¥¦ÅüÂå¼Õ¤È¿À·Ð¤Î½ý³²Äñ¹³À­¤ÇÍ­Íø¤Ç¤¢¤ë¡£
R.Michael¡¡Auson¡¡¡¡¡¡Ï·²½¹ñΩ¸¦µæ½ê¡¡¡¡¥¢¥á¥ê¥«
PNAS¡¡May¡¡13¡¡¡¡2003. vol.100 6216-6220


¿©»öÀ©¸Â¤Ï¡¢¥¤¥ó¥·¥å¥ê¥ó´¶¼õÀ­¤ÎÁý²Ã¡¢¥¹¥È¥ì¥¹¤ËÂФ¹¤ëÂÑÀ­»à˴Ψ¤Î¸º¾¯¡¢Ä¹¼÷¤Ê¤ÉÍÍ¡¹¤ÊÍøÅÀ¤ò»ý¤Ã¤Æ¤¤¤ë¡£

¤½¤Î¥á¥«¥Ë¥º¥à¤Ïʬ¤«¤Ã¤Æ¤¤¤Ê¤¤¤¬¡¢Ä¹´ü¤Ë¤ï¤¿¤Ã¤Æ¥«¥í¥ê¡¼À©¸Â¤¹¤ë»ö¤¬É¬ÍפȤµ¤ì¤Æ¤¤¤Þ¤¹¡£C57BL/6¥Þ¥¦¥¹¤òÍѤ¤¡Ö¼¡¤ÎÆü¤ÎÀä¿©¡×¡Ê¿©¤Ù¤¿¤¤¤À¤±¿©¤Ù¡¢¼¡¤ÎÆüÀä¿©¤Î·«¤êÊÖ¤·¡Ë¤È¤¤¤¦¼Â¸³¤ò¤¹¤ë¤È¿©»öÎ̤ϸº¾¯¤»¤º¡¢ÂνŤ⸺¾¯¤·¤Ê¤«¤Ã¤¿¡£(¿©¤Ù¤ì¤ëÆü¤Ë2ÇÜ¿©¤Ù¤Æ¤¤¤ë¤Î¤Ç)¡¡¤½¤ì¤Ë¤â´Ø¤ï¤é¤º¡Ö¼¡¤ÎÆüÀä¿©¡×¤Ï¡¢¡Ö¥«¥í¥ê¡¼À©¸Â¡×¡Ê60¡ó¤ËÀ©¸Â¡Ë¤·¤¿¥Þ¥¦¥¹¤è¤ê¤â·ìÃ楰¥ë¥³¡¼¥¹Ç»ÅÙ¡¢¥¤¥ó¥·¥å¥ê¥óÎÌ¡¢¿À·ÐºÙ˦¤Î½ý³²Äñ¹³À­¤Ê¤É¤Ç¤è¤êÎɤ«¤Ã¤¿¡£¡Ö¼¡¤ÎÆüÀä¿©¡×¤Ï¥Ö¥É¥¦ÅüÂå¼Õ¡¢¿À·Ð¤Î½ý³²Äñ¹³À­¤¬¤¹¤°¤ì¤Æ¤ª¤ê¡¢¥«¥í¥ê¡¼¤ÎÎ̤Ȥϴط¸¤Ê¤¤¡£


²òÀâ

¿©»ö¤ò60¡ó¤º¤Ã¤ÈÀ©¸Â¤¹¤ë¤è¤ê¡Ö¼¡¤ÎÆüÀä¿©¡×¤ÎÊý¤¬¥Ò¥È¤Ë¤â¤Í¤º¤ß¤Ë¤â¡¢Ï·²½¤òÍÞ¤¨Ä¹À¸¤­¤Ç¤­¤ë¡£¤È¤¤¤¦¤³¤È¤ò¤³¤ÎÏÀʸ¤Ï¼¨¤·¤Æ¤¤¤Þ¤¹¡£¿©¤Ù¤ì¤ë»þ¤Èµ²¤¨¤ë»þ¤Î¸òÂØ¡¢ÌîÀ¸¤ÎÀ¸¤­Êª¤Ê¤éÅöÁ³¤Î»ö¤Ç¡¢¤½¤ì¤ËŬÍѤ¹¤ëÍͤËÂΤλÅÁȤߤ¬ºî¤é¤ì¤Æ¤¤¤ëÍͤʤΤǤ¹¡£¤½¤ì¤À¤«¤é¡¢¿©¤Ùʪ¤¬°î¤ì¤Æ¤¤¤ëÀè¿Ê½ô¹ñ¤Ç¤Ï¡¢ÅüǢɤò»Ï¤á¤È¤·¤Æ¡Ö¿©¤Ù²á¤®¡×¤Îɤ¬°î¤ì¤Æ¤¤¤ë¤Î¤Ç¤¹¡£

Àݤä¿¿©»ö¤Ï¼¡¤Îµ²¤¨¤ËÈ÷¤¨¤Æ¡¢¤¹¤°¤Ë»éËäʤɤȤ·¤ÆÂÎÆâ¤ËÃߤ¨¤Æ¤·¤Þ¤¦¤Î¤Ç¤¹¡£

¡Ê°Ëß·¡Ë

¡Ê2007/12/21 ·ÇºÜ¡Ë

¥³¥ì¥¹¥Æ¥í¡¼¥ëÄã²¼Ìô¤ÎºÇ¿·¤ÎÃθ«¡¢¿·¤·¤¤¥Ç¡¼¥¿¡¼¡¢¿·¤·¤¤µ¿Ìä

ÏÀʸ¤Ç¾Ò²ð¤·¤Þ¤¹

Recent cholesterol-lowering drug trials :new data, new question
¥³¥ì¥¹¥Æ¥í¡¼¥ëÄã²¼Ìô¤ÎºÇ¿·¤ÎÃθ«¡¢¿·¤·¤¤¥Ç¡¼¥¿¡¼¡¢¿·¤·¤¤µ¿Ìä
Michel de Lorgeril Joseph Fourier-Grenoblel£±Âç³Ø
J.Lipid Nutr .vol.19,­â1¡Ê2010¡Ë


2008ǯ¡½2009ǯ¤Ëȯɽ¤µ¤ì¤¿¥³¥ì¥¹¥Æ¥í¡¼¥ëÄã²¼Ìô¤Ï¸ú²Ì¤Ê¤·¡ÊENHANCE, SEAS, GISSI-HF, AURORA¡Ë¤«ÌÀ¤é¤«¤ËÊиþ¤·¤Æ¤ª¤ê¡¢¿®Íê¤Î¤ª¤±¤Ê¤¤¡ÊJUPITER¡Ë¸¦µæ¤Ë¤Ê¤Ã¤Æ¤¤¤Þ¤¹¡£»äã¤Ï¤³¤ì¤é¤Î¥³¥ì¥¹¥Æ¥í¡¼¥ëÄã²¼Ìô¤¬¸ú²Ì¤Ê¤·¤È¤¤¤¦·ëÏÀ¤ò¡¢¤É¤¦ÀâÌÀ¤Ç¤­¤ë¤Î¤À¤í¤¦¤«?¤³¤ÎÏÀʸ¤Ç¡¢Ãø¼Ô¤Ï¤³¤ì¤é¤Î¸¦µæ¤òºÆ¸¡Æ¤¤·¤Þ¤È¤á¤Æ¡¢¤³¤ì¤é¤ÎºÇ¿·¤Î¸¦µæ·ë²Ì¤Ë¤Ä¤¤¤Æ¥³¥á¥ó¥È¤·¤Þ¤¹¡£

Ʊ»þ¤Ë¡¢½ÅÍפʤ³¤È¤Ï2005ǯ¤«¤é2007ǯ¤Ë¤«¤±¤Æȯɽ¤µ¤ì¤¿¥³¥ì¥¹¥Æ¥í¡¼¥ëÄã²¼Ìô¸¦µæ¤Î¤Û¤È¤ó¤É¤¬¡¢¸ú²Ì¤ËÈÝÄêŪ¤â¤·¤¯¤Ï¤¢¤¤¤Þ¤¤¤Ê¤â¤Î¤À¤Ã¤¿¤³¤È¤Ç¤¹¡£

2005ǯ¤Ë¥Ð¥¤¥ª¥Ã¥¯¥¹»ö·ï(ÌõÃí²¼)¤¬¤¢¤ê¡¢Î×¾²¸¦µæ¤Ë¤Ä¤¤¤Æ¿·¤·¤¤µ¬À©¤¬¶¯²½¤µ¤ì¤Æ¤¤¤Þ¤¹¡£


(ÌõÃí¡¡¥Ð¥¤¥ª¥Ã¥¯¥¹»ö·ïŽ¥Ž¥Ž¥À½Ìô¥á¡¼¥«¡¼¥á¥ë¥¯¼Ò¤¬ÄÃÄËÌô¥Ð¥¤¥ª¥Ã¥¯¥¹¤ÎÉûºîÍѤòÃΤê¤Ê¤¬¤éÈÎÇ䤷¡¢¿´¶Ú¤³¤¦¤½¤¯¤Ê¤É¤Ç»àË´¼Ô¤¬½Ð¤¿»ö·ï¡£¤³¤Î»ö·ï¤ÎºÛȽ¡Ê3Ëü·ï¡Ë¤Ç¥á¥ë¥¯¼Ò¤¬ÏÀʸ¤ÎÃø¼Ô¤ò¥´¡¼¥¹¥È¥é¥¤¥¿¡¼¤Ë¤·¤Æ¤¤¤ë¤Ê¤É¿¤¯¤Î°Õ¿ÞŪ¤Ê¾ðÊóÁàºî¤¬¤¢¤ê¡¢¤³¤ì¤é¤Î»ö¤òËɤ°¤¿¤á¡¢FDA(¥¢¥á¥ê¥«¿©ÉÊ°åÌôÉʶÉ)¤¬µ¬À©¤ò¶¯²½¤·¤¿¤â¤Î¡£¤½¤ÎÆâÍƤȤ·¤Æ­¡Î×¾²¸¦µæ¤ÎÀë¸À¤ÎµÁ̳²½¡Ê¸¦µæ¤ò»Ï¤á¤¿¤È¤¤¤¦¤³¤È¡Ë¡¢­¢¸¦µæ¤Î·ë²Ì¤¬¤½¤ÎÌô¤Î¸ú²Ì¤Ë¹¥¤Þ¤·¤¯¤Ê¤¤¾ì¹ç¤Ç¤â¸øɽ¤¹¤ë¤³¤È¡¢¤Î2ÅÀ¤Ë¤Ê¤Ã¤Æ¤¤¤Þ¤¹¡£)

¤³¤ì¤é¤Î¤³¤È¤ò¤¤¤Ã¤·¤ç¤Ë¤·¤Æ¹Í¤¨¤Æ¤ß¤ë¤È¡¢2008ǯ¡Á2009ǯ¤Î¸¦µæ¤â´Þ¤á¤Æ¡¢ºÇ¿·¤Î¸¦µæ¤¬¼¨¤·¤Æ¤¤¤ë¤³¤È¡Ê2005ǯ¡Á2009ǯ¡Ë¤Ï¡¢°ÊÁ°¤Î¸¦µæ¡Ê2004ǯ°ÊÁ°¡Ë¤¬¥¹¥¿¥Á¥ó¡Ê¥³¥ì¥¹¥Æ¥í¡¼¥ëÄã²¼Ìô¡Ë¤Ë´Ø¤·¤Æ¹â¤¤¸ú²Ì¤ò¼¨¤·¤¿¸¦µæ¤¬¡¢(Æä˴§¾õ¿´Â¡É¤Î2¼¡ÅªÍ½Ëɤ˸ú²Ì¤ò¼¨¤·)°åÎÅ´Ø·¸¼Ô¤Î¥¬¥¤¥É¥é¥¤¥óºî¤ê¤Î´ð¤Ë¤Ê¤Ã¤¿¡£¤½¤ì¤é¤Î¸¦µæ¤ò¿µ½Å¤Ë¡¢À½Ìô¶È³¦¤È¤ÏÆÈΩ¤·¤¿ÀìÌç²È¤Ë¤è¤Ã¤Æ¡¢ºÆɾ²Á¤µ¤ì¤ë¤Ù¤­¤Ç¤¢¤ë¤³¤È¤ò¼¨¤·¤Æ¤¤¤ë¡£


¡ÊÌõÃí¡¡¸½ºß¤Î¥¬¥¤¥É¥é¥¤¥ó¡¾Î㤨¤ÐÁí¥³¥ì¥¹¥Æ¥í¡¼¥ëÃÍ220°Ê²¼¤È¤¤¤¦Íͤʥ¬¥¤¥É¥é¥¤¥ó¤Î´ð¤Ë¤Ê¤Ã¤¿1994ǯ¡Á2004ǯ¤Ë¤«¤±¤Æ¤Î¡¢¥³¥ì¥¹¥Æ¥í¡¼¥ëÄã²¼Ìô¤Î¹â¤¤¸ú²Ì¤ò¼¨¤·¤¿ÏÀʸ¤Ëµ¿¤¤¤¬¤¢¤ê¡¢¤½¤ì¤é¤Î¸¦µæ¤òÀ½Ìô¶È³¦¤È¤ÏÆÈΩ¤Î¡Ê̵±ï¤Î¡ËÀìÌç²È¤ÇºÆɾ²Á¤¹¤Ù¤­¤À¤È¸À¤Ã¤Æ¤¤¤Þ¤¹¡£2005ǯ¤ËÎ×¾²¸¦µæµ¬À©¤Î¶¯²½¤¬¤¢¤ê¡¢¤½¤ì°Ê¸å¤ÎÏÀʸ¤Î·ë²Ì¤Ç¤Ï¥³¥ì¥¹¥Æ¥í¡¼¥ëÄã²¼Ìô¤Î¸ú²Ì¤¬ÈÝÄê¤â¤·¤¯¤Ï¤¢¤¤¤Þ¤¤¤À¤«¤é¤Ç¤¹¡£¡Ë

¼¡¤Îµ¿ÌäÅÀ¤Ï¡¢¥³¥ì¥¹¥Æ¥í¡¼¥ë¤òÄã²¼¤µ¤»¤ë¤³¤È¤¬¿´·ì´ÉÉÂ(»à)¤ÎͽËɤˤĤʤ¬¤ë¤È¤¤¤¦ÍýÏÀ¤òºÆɾ²Á¤¹¤Ù¤­»þ¤Ê¤Î¤«¤É¤¦¤Ê¤Î¤«¤È¤¤¤¦ÅÀ¤Ç¤¹¡£


¡ÊÌõÃí¡¡Áí¥³¥ì¥¹¥Æ¥í¡¼¥ëÃͤˤĤ¤¤Æ¡¢260ÄøÅÙ¤ÎÊý¤¬Ä¹À¸¤­¤À¤È¤¹¤ëÏÀʸ¤â¤¢¤ê¤Þ¤¹¡£¸½ºß¤Î¥¬¥¤¥É¥é¥¤¥ó¤Î´ð½àÃÍ220°Ê¾å¤Î¿Í¤ÏÆüËܿͤǤâ40¡ó¤â¤ª¤ê¡¢ËÜÅö¤Ëɵ¤¤Ê¤Î¤«¤È¤¤¤¦µ¿Ì䤬»Ä¤ê¤Þ¤¹¡£¡Ë


²òÀâ

¤â¤·¡¢À½Ìô²ñ¼Ò¤¬²ñ¼Ò¤ËÉÔÍø¤Ê»î¸³Ìô¤Î¸ú²Ì¤òȯɽ¤»¤º¡¢¸ú²Ì¤¢¤ê¤ÎÏÀʸ¤À¤±¤òȯɽ¤·¤Æ¤¤¤¿¤é¡¢¤É¤¦¤¤¤¦¤³¤È¤Ë¤Ê¤ë¤Î¤«¡¢º£²ó¤ÎÏÀʸ¤Ï¥³¥ì¥¹¥Æ¥í¡¼¥ëÄã²¼Ìô¤Ë¤½¤Îµ¿¤¤¤¬¤¢¤ë¡¢¤È¤¤¤Ã¤Æ¤¤¤Þ¤¹¡£ÆüËܤǤϡ¢Ã˽÷Ìä¤ï¤º¡¢¥³¥ì¥¹¥Æ¥í¡¼¥ëÃͤ¬¹â¤¤¿Í¤Ï¡¢¥³¥ì¥¹¥Æ¥í¡¼¥ëÄã²¼Ìô¤ò½èÊý¤µ¤ì¤Æ¤¤¤Þ¤¹¤¬¡¢¤³¤ì¤ÏÆüËܤÀ¤±¤Ç¡¢¥¢¥á¥ê¥«Ž¥¥è¡¼¥í¥Ã¥Ñ¤Ç¤Ï½èÊý¤µ¤ì¤ë¤Î¤ÏÃËÀ­¤À¤±¤Ç¤¹¡£¥³¥ì¥¹¥Æ¥í¡¼¥ëÄã²¼Ìô¤Ë¤ÏÉûºîÍѤ¬¤¢¤ê¤Þ¤¹¡£¡Ê¶ÚÆù¤¬¿ê¤¨¤Æ¤¤¤¯Éµ¤¡Ö»ä¤ÏÌô¤Ë»¦¤µ¤ì¤ë¡×Ê¡ÅļÂÃø¡¡¸¸Å߼˴©¡Ë°äÅÁŪ¤Ê¹â¥³¥ì¥¹¥Æ¥í¡¼¥ë¾É¤Î¿Í¤Ë¤Ä¤¤¤Æ¤Ï¤ï¤«¤ê¤Þ¤»¤ó¤¬¡¢Æ°Ì®¹Å²½¤Î¸¶°ø¤Ï¡¢»À²½¤·¤¿¥³¥ì¥¹¥Æ¥í¡¼¥ë¤Ç¤¢¤ê¡¢¥¿¥Ð¥³¤Ê¤É¤Î±Æ¶Á¤¬¶¯¤¤¤Î¤Ç¤¹¡£

¡Ê°Ëß·¡Ë

¡Ê2011/4/7 ·ÇºÜ¡Ë

¥í¥Õ¥§¥³¥­¥·¥Ö¤Ë´Ø¤¹¤ëÏÀʸ¤Ï¥´¡¼¥¹¥È¥é¥¤¥¿¡¼¤À¤Ã¤¿

ÏÀʸ¤Ç¾Ò²ð¤·¤Þ¤¹

Guest authorship and ghostwriting in publications related to rofecoxib. : a case study of industry documents from rofecoxib litigation
¥í¥Õ¥§¥³¥­¥·¥Ö¤Ë´Ø¤¹¤ëÏÀʸ¤Ï¡¢Ãø¼Ô¤ò¼Ú¤ê¤Æ¤­¤¿¤ê¡¢¥´¡¼¥¹¥È¥é¥¤¥¿¡¼¤À¤Ã¤¿¡§¥í¥Õ¥§¥³¥­¥·¥ÖºÛȽ¤Î²ñ¼Ò¡Ê¥á¥ë¥¯¼Ò¡Ë¤Îʸ½ñ¤Î¸¦µæ
Ross. J S.¡¡¡¡¥Þ¥¦¥ó¥È¥·¥Ê¥¤°å³Ø¹»¡¥¥¢¥á¥ê¥«¡¥
JAMA, 2008 Apr. 16:299(15) : 1800-12.


¥í¥Õ¥§¥³¥­¥·¥Ö¡Ê¾¦ÉÊ̾¥Ð¥¤¥ª¥Ã¥¯¥¹…¥á¥ë¥¯¼Ò¤¬ÈÎÇ䤷¤¿¡¢¥¢¥ì¥ë¥®¡¼ÍÑÄÃÄËÌô¤Ç¿´Â¡¤Ê¤É¤Ø¤ÎÉûºîÍѤ¬¸«¤Ä¤«¤êÈÎÇäÃæ»ß¤Ë¤Ê¤Ã¤¿¡Ë¤Ë´Ø¤·¤Æ¥á¥ë¥¯¼Ò¤È¤ÎºÛȽ¤ÇÌÀ¤é¤«¤Ë¤Ê¤Ã¤¿²ñ¼Ò¦¤Î1996ǯ¤«¤é2004ǯ¤Îʸ½ñ¤ò´ð¤Ë¤·¤¿¡£

Ìó250¤Îʸ½ñ¤òÄ´ºº¤·¤¿¡¥Î×¾²¸¦µæÏÀʸ¤Îȯɽ¤Ë´Ø¤·¤Æ¡¢¥á¥ë¥¯¼Ò¤Î¼Ò°÷ñÆȤ⤷¤¯¤Ï¡¢Â¾¤Î°å³Ø·Ï½ÐÈDzñ¼Ò¤È¶¦Æ±¤·¤ÆÁð¹Æ¤òºî¤ê¡¢¤½¤Î¸å¡¢³°Éô¤ÎÂç³Ø¤Ê¤É¤Î¸¦µæ¼Ô¤òÃø¼Ô¤Ë¤·¤Æ¤¤¤¿¡¥¾·¤¤¤¿³°Éô¤ÎÃø¼Ô¤Ï¡¢Ãø¼ÔÍó¤Î£±ÈÖÌÜ¡¢¤â¤·¤¯¤Ï£²ÈÖÌܤ˽ñ¤«¤ì¤ë¤³¤È¤¬Â¿¤«¤Ã¤¿¡¥ÁíÀâ¡Ê¤Þ¤È¤á¤ÎÏÀʸ¡Ë¤Ë´Ø¤·¤Æ¤Ï¡¢¥á¥ë¥¯¼Ò¤Î±Ä¶È¿¦¼Ò°÷¤¬Áð¹Æ¤Î¥×¥é¥ó¤òºî¤ê¡¢°å³Ø·Ï½ÐÈDzñ¼Ò¤È¥´¡¼¥¹¥È¥é¥¤¥¿¡¼·ÀÌó¤ò·ë¤Ó¡¢³°Éô¤ÎÂç³Ø¤Ê¤É¤Î¸¦µæ¼Ô¤òÃø¼Ô¤È¤·¤Æ¾·¤¤¤¿¡¥¾·¤«¤ì¤¿Ãø¼Ô¤ÏÉáÄÌ£±¿Í¤Ç¤ª¶â¤ò»Ùʧ¤Ã¤¿¡¥96ÏÀʸ¤ÎÆâ¡¢92¡ó¤ÎÎ×¾²¸¦µæÏÀʸ¤Ë¤Ï¥á¥ë¥¯¼Ò¤ÎºâÀ¯±ç½õ¤¬³«¼¨¤µ¤ì¤Æ¤¢¤Ã¤¿¡¥¤·¤«¤·¡¢ÁíÀâÏÀʸ¡Ê72ËÜÃæ¤Î36ËܡˤÎ50¡ó¤·¤«¥á¥ë¥¯¼Ò¤ÎºâÀ¯±ç½õ¤ò³«¼¨¤·¤Æ¤Ê¤«¤Ã¤¿¡£
 

(2011/4/21 ·ÇºÜ¡Ë

¥ß¥³¥Ð¥¯¥Æ¥ê¥¦¥à¤Î¥Ñ¥é·ë³Ë¶Ý

ÏÀʸ¤Ç¾Ò²ð¤·¤Þ¤¹

MYCOBACTERIUM AVIUM PARATUBERCULOSIS:Infrequent Human Pathogen or Public Health Threat?
¥ß¥³¥Ð¥¯¥Æ¥ê¥¦¥à¤Î¥Ñ¥é·ë³Ë¶Ý¡§µ©¤Ë¤·¤«µ¯¤­¤Ê¤¤¿Í¤Ø¤Îɸ¶ÂΤ«¡¢¸ø¶¦±ÒÀ¸¤Ø¤Î¶¼°Ò¤«¡©
A Report from the American Academy of Microbiology


¥¯¥í¡¼¥óɤÏÈï³²¤¬¿ÓÂç¤Ç¡¢¸¶°ø¡¦¼£ÎÅË¡¤ò¸«¤Ä¤±¤ë¤Î¤¬Æñ¤·¤¤¡£ËÌ¥¢¥á¥ê¥«¤Ç80Ëü¿Í¤¬´¶À÷¤·¡¢²¼Î¡¡¦½Ð·ì¡¦Ä²¤Î¾ã³²¤Ê¤É¡¢°ßIJ¤Î¾É¾õ¤Ë¶ì¤·¤ó¤Ç¤¤¤ë¡£¿ô¥ö·î¡¢»þ¤Ë¤Ï¿ôǯ³¤¯ÍÍ¡¹¤ÊÁÈ¿¥¤Î¾É¾õ¤ÇĹ´ü¤ËÅϤäÆÆü¾ïÀ¸³è¤Ë»Ù¾ã¤ò¤­¤¿¤·¤Æ¤­¤¿¡£

¸¦µæ°÷¡¦Î×¾²°å¤Ï¡¢°ìÏ¢¤ÎÍ×°ø¤¬Â·¤¦¤È¥¯¥í¡¼¥óɤ¬È¯¾É¤¹¤ë¤È¤·¤Æ¤¤¤ë¡£¤¢¤ë°äÅÁŪ·Á¼Á¤ò¼õ¤±·Ñ¤®¡¢´Ä¶­¤Î»É·ã¤ò¼õ¤±¡¢²á¾ê¤ÊÌȱ֤òµ¯¤³¤·¡¢±ê¾É¤òµ¯¤³¤¹¤³¤È¤Ç¤¢¤ë¡£¤½¤ÎÁȤ߹ç¤ï¤»¤Ë¤è¤ê´µ¼Ô¤ÎɾɤÏÉý¹­¤¯ÍÍ¡¹¤Ç¤¢¤ë¡£´µ¼Ô¡¢²È²¡¢ÃÏ°è¡¢·ò¹¯´ÉÍý¥·¥¹¥Æ¥à¤ËÂФ¹¤ë¤³¤Îɵ¤¤Î·ÐºÑŪ¡¦¼Ò²ñŪ¤Ê¥¤¥ó¥Ñ¥¯¥È¤ÏÂ礭¤¤¡£

Ť¤´Ö¡¢Ä²¤ÎËýÀ­±ê¾É¤À¤È¹Í¤¨¤é¤ì¤Æ¤ª¤ê¡¢±ê¾É¤òÍÞ¤¨¤ë¼£ÎŤ¬¹Ô¤ï¤ì¤Æ¤¤¤¿¤¬¡¢¥¯¥í¡¼¥óɼ«ÂΤò¼£ÎŤ¹¤ë¤â¤Î¤Ç¤Ï¤Ê¤¤¡£±ê¾É¤ÏÉáÄÌ¡¢Âγ°Í³Íè¤ÎÀ¸Êª¡¢ÌµÀ¸Êª¡ÊÇËÊÒ¡Ë¡¢°­À­¤ÎºÙ˦¡Ê¤¿¤È¤¨¤Ð¤¬¤óºÙ˦¡Ë¡¢ÈùÀ¸Êª¡Ê¥Ð¥¯¥Æ¥ê¥¢¡¢¥¦¥¤¥ë¥¹¡¢¶Ý¡Ë¤Ê¤É¤Ë¤è¤Ã¤Æµ¯¤³¤ë¡£±ê¾É¤Î¸¶°ø¤¬ÇÓ½ü¤µ¤ì¤ë¤Þ¤Ç¡¢Çò·ìµå¤¬»¦¶Ý¤·Â³¤±¤ë¡£¸¶°ø¤¬ÇÓ½ü¤µ¤ì¤ì¤Ð±ê¾É¤¬¼ý¤Þ¤ë¡£

°äÅÁ»Ò¤Î°ã¤¤¤Ë¤è¤Ã¤Æ¡¢¤¢¤ë¼ï¤Î¥Ð¥¯¥Æ¥ê¥¢¤ËÈ¿±þ¤Ç¤­¤Ê¤¤¿Í¤¬¤¤¤Æ¡¢´Ä¶­Í×°ø¤¬´Ø·¸¤·¤Æ¤¤¤ë¤È»×¤ï¤ì¤ë¡£¥¯¥í¡¼¥óɤÏÈùÀ¸Êª¤Ë¤è¤ê°ú¤­µ¯¤³¤µ¤ì¤¿µ¿¤¤¤Î¤¢¤ë¾ì¹ç¤¬¤¢¤ë¡£¥¯¥í¡¼¥óɤϤ¢¤ëÆÃÄê¤Îɵ¤¤È¤¤¤¦¤è¤ê¤Ï¾É¸õ·²¤Ë¶á¤¯¡¢Éý¹­¤¤¾É¾õ¤ò»ý¤Á¡¢¸¶°ø¤â£±¤Ä¤Ë¤·¤Ü¤ì¤Ê¤¤¡£¥ß¥³¥Ð¥¯¥Æ¥ê¥¦¥à¤ÈÂçIJ¶Ý¡ÊEschelichia coli¡Ë¤ÎÊÑ°ÛÂΤ¬¹Í¤¨¤é¤ì¤ë¡£´¶À÷¸¶°ø¤¬£±¤Ä¤Ç¤Ï¤Ê¤¤¤³¤È¤Ç¡¢¸¶°ø¤È¼£ÎÅË¡¤ò¸«¤Ä¤±¤è¤¦¤Ë¤â²¿¤Ë¤·¤Ü¤ì¤Ð¤¤¤¤¤Î¤«¤ï¤«¤é¤Ê¤¤¡£

¸¶°ø¤Î£±¤Ä¤Ë¡¢²ÈÃܤΤâ¤ÄMAP¡ÊMycobacterium avium¤Î°¡¼ïparatuberculosis¡Ë¤Î²ÄǽÀ­¤¬¤¢¤ê¡¢¥¯¥í¡¼¥óÉ´µ¼Ô¤ÏÄ̾ï¤Î¿Í¤Î£·Çܤγä¹ç¤Ç·ìÃæ¤äÁÈ¿¥¤ËMAP¤ò¤â¤Ã¤Æ¤¤¤ë¤¿¤á¡¢MAP¤¬¥¯¥í¡¼¥óɤȴØÏ¢¤¬¤¢¤ë¤³¤È¤ÏÌÀÇò¤Ç¤¢¤ë¡£½ÅÍפʤΤϡ¢MAP¤¬¥¯¥í¡¼¥óɤò°ú¤­µ¯¤³¤¹¤Î¤Ï¡¢Ä¾ÀÜŪ¤Ê¤Î¤«´ÖÀÜŪ¤Ê¤Î¤«¡¢¤È¤¤¤¦¤³¤È¤Ç¤¢¤ë¡£¤â¤·¤½¤¦¤Ç¤¢¤ì¤Ð¡¢´¶À÷¤Î·ÐÏ©¡¢ËɽüË¡¡¢¼£ÎÅË¡¤ò·èÄꤹ¤ëɬÍפ¬¤¢¤ë¡£

¥¢¥á¥ê¥«¤Ç¤Îή¹Ô¤¬¤¬¤ó´µ¼Ô¤Î¿ô¤òĶ¤¨¤¿¤Ë¤â¤«¤«¤ï¤é¤º¡¢¥¯¥í¡¼¥óɤϽ¸ÃæŪ¤Ë¸¦µæ¤¬¹Ô¤ï¤ì¤Ê¤¤¡£ÊƹñÈùÀ¸Êª³Ø²ñ¡ÊAAM¡Ë¤ÏÍÍ¡¹¤ÊʬÌî¤ÎÀìÌç²È¤ò¾¤½¸¤·¤Æ²ñµÄ¤ò¹Ô¤¤¡¢¥¯¥í¡¼¥óɤËMAP¤¬³Î¤«¤ËºîÍѤ¹¤ëµ¿¤¤¤¬¤¢¤²¤é¤ì¤¿¡£

¡üMAP¤Ï±øÀ÷¤µ¤ì¤¿ÅÚ¾í¤È¿å¤Ë¸ºß¤·¡¢¥¯¥í¡¼¥óɤδĶ­Í×°ø¤È´Ø·¸¤·¹ç¤Ã¤Æȯɤˤ¤¤¿¤ë¡£
¡üMAP¤Ï¥¯¥í¡¼¥óɤȻ÷¤Æ¤¤¤ë¥è¡¼¥ÍÉ¡ʲÈÃÜÅùưʪ¤Î°äÅÁÉ¡ˤθ¶°ø¤Ç¤¢¤ê¡¢É°ø¤¬¤ï¤«¤Ã¤Æ¤¤¤ë¤Î¤Ç¡¢¥¯¥í¡¼¥óɤÎÍ×°ø¤Èɵ¤¤È¤Î´Ø·¸¤òÍ¿¤¨¤Æ¤¯¤ì¤ë¡£
¡üMAP¤ÏÄã²¹»¦¶Ý¤Ç¤Ï»àÌǤ»¤º¡¢¥¢¥á¥ê¥«¤ÈEU¤ÇÇä¤é¤ì¤Æ¤¤¤ë¥ß¥ë¥¯¤«¤é¸¡½Ð¤µ¤ì¤Æ¤¤¤ë¡£¥è¡¼¥Íɤ˴¶À÷¤·¤¿²ÈÃܤÎÆýÀ½ÉʤäÆù¤«¤é¤âMAP¤¬¸«¤Ä¤«¤Ã¤Æ¤¤¤ë¡£¥¯¥í¡¼¥óÉ´µ¼Ô¤ÎMAP¤Ø¤Î´¶À÷¥ë¡¼¥È¤È¤Ê¤Ã¤Æ¤¤¤ë¡£
¡ü¤¢¤ë¥ß¥³¥Ð¥¯¥Æ¥ê¥¢¤ËÍ­¸ú¤Ê¹³À¸Êª¼Á¤Ï¡¢MAP¤ËÆò½¤·¤Æ¤¤¤Ê¤¤¹³À¸Êª¼Á¤Ç¤¢¤Ã¤Æ¤â¡¢¥¯¥í¡¼¥óɤÎɾɤ¬´ËϤµ¤ì¤ë¾ì¹ç¤¬¤¢¤ë¡£

¤³¤ì¤é¤ÎÄ´ºº¤Ë¤è¤Ã¤Æ¾õ¶·Åª¤Ë¥¯¥í¡¼¥óÉ¤θ¶°ø¤ËMAP¤¬´Þ¤Þ¤ì¤ë¤³¤È¤Ï´Ö°ã¤¤¤Ê¤µ¤½¤¦¤Ç¤¢¤ë¡£

°ìÊý¤Ç¡¢·èÄêŪ¤Ë¥¯¥í¡¼¥óÉ¤θ¶°ø¤Ç¤¢¤ë¤È¤«¡¢Âç¿¿ô¤Î¥¯¥í¡¼¥óÉ¤θ¶°ø¤Ç¤¢¤ë¤«¤Ï¡¢ÁÈ¿¥¼«ÂΤΤ狼¤ê¤Ë¤¯¤¤ÆÃÀ­¤Ë¤è¤Ã¤Æ˸³²¤µ¤ì¤Æ¤¤¤ë¡£MAP¤Ë¶á¤Å¤±¤ë¡¢Éý¹­¤¯ÍøÍѲÄǽ¤ÊÍ­¸ú¤ÊÎ×¾²ÅªÊýË¡¤ï¤«¤Ã¤Æ¤¤¤Ê¤¤¡£¤â¤Ã¤È¤â½ÅÍפʤΤϡ¢»ñ¸»¡¢ºâÀ¯¡¢µ»½Ñ¤ÎÉÔ­¤Ç¤¢¤ê¡¢MAP¤¬Éµ¤¤Î²áÄø¤Ë´Þ¤Þ¤ì¤ë¤«¤É¤¦¤«¤ò·è¤á¤ë¤¬É¬ÍפǤ¢¤ë¡£

¸½¾õ¤Ï¡¢º£¤â³¤¤¤Æ¤¤¤ëMAP¤Ë´¶À÷¤·¤¿²ÈÃܤÎÀ¸»º¤ÈήÄ̤¬½ÅÍפʲÝÂê¤Ç¤¢¤ë¡£Áá´üȯ¸«¤È¿©Îȶ¡µë¤ÎÂкö¤¬É¬ÍפǤ¢¤ë¡£

­¡¿Í¤Èưʪ´Ö¤Î´¶À÷¤¬¤É¤Î¤è¤¦¤Ëµ¯¤³¤ë¤«¡¢­¢¿Í¤ÏMAP¤Ë¤è¤Ã¤Æ´¶À÷¤¹¤ë¤Î¤«¡¢¤ò²òÌÀ¤·¡¢¸¶°ø¤È¼£ÎÅË¡¤ò¸«½Ð¤¹É¬Íפ¬¤¢¤ë¡£

¡Ê2012/07/30 ·ÇºÜ¡Ë

¿¢ÊªÀ­Æý»À¶Ý¤Î¿·À¸»ù¤ÎIJ¤Ø¤Î¥·¥ó¥Ð¥¤¥ª¥Æ¥£¥Ã¥¯ÅêÍ¿¤Ë¤è¤ëÄêÃå

ÏÀʸ¤Ç¾Ò²ð¤·¤Þ¤¹

Long-term colonization of a Lactobacillus plantarum synbiotic preparation in the neonatal gut
¿¢ÊªÀ­Æý»À¶Ý¤Î¿·À¸»ù¤ÎIJ¤Ø¤Î¥·¥ó¥Ð¥¤¥ª¥Æ¥£¥Ã¥¯ÅêÍ¿¡Ê¶Ý¤È¤½¤Î¥¨¥µ¤ÎƱ»þÅêÍ¿¡Ë¤Ë¤è¤ëĹ´ü´Ö¤ÎÄêÃå
Panigrahi P¡¡¥á¥ê¡¼¥é¥ó¥É°å²ÊÂç³Ø¡¡¥¢¥á¥ê¥«
J Pediatr Gastroenterol Nutr 2008 Jul;47(1):45-53


¥×¥í¥Ð¥¤¥ª¥Æ¥£¥Ã¥¯¡¢¥×¥ì¥Ð¥¤¥ª¥Æ¥£¥Ã¥¯¡¢¥·¥ó¥Ð¥¤¥ª¥Æ¥£¥Ã¥¯¡Ê¥×¥í¥Ð¥¤¥ª¥Æ¥£¥Ã¥¯¤È¥×¥ì¥Ð¥¤¥ª¥Æ¥£¥Ã¥¯¤ÎÁȤ߹ç¤ï¤»¡Ë¤¬¤Þ¤¹¤Þ¤¹·ò¹¯¤ÎÍÍ¡¹¤Ê¶ÉÌ̤˻Ȥï¤ì¤ëÍͤˤʤäƤ­¤Æ¤¤¤Þ¤¹¡£

¡ÊIJ¤Ø¤Î¡ËÄêÃå¤È¤¤¤¦¤³¤È¤¬À®¸ù¤¹¤ë¤¿¤á¤Î½ÅÍפÊÍ×ÁǤǤ¹¤¬¡¢¤½¤ÎÍͤÊÎ×¾²¸¦µæ¤Ï¤Û¤È¤ó¤É¤¢¤ê¤Þ¤»¤ó¡£¿·À¸»ù¤äÍÄ»ù¤Ê¤É¤Ç¤Ï¤â¤Ã¤È¤âɬÍפÊÂоݤǤ¹¤¬¡¢¹¹¤Ë¸¦µæ¤Ï¾¯¤Ê¤¤¤Ç¤¹¡£¤³¤Î¸¦µæ¤Ï¿·À¸»ù¤Ë7Æü´Ö¥·¥ó¥Ð¥¤¥ª¥Æ¥£¥Ã¥¯ÅêÍ¿¤ò¤·¤Æ¡¢ÄêÃåǽÎÏ¡¢ÂÑÀ­¡¢ÊØÃæ¤Î¶Ý¤½¤¦¤Ø¤Î±Æ¶Á¤òÄ´¤Ù¤ëÌÜŪ¤Ç¹Ô¤ï¤ì¤Þ¤·¤¿¡£


ÊýË¡

½ÐÀ¸»þ1800g°Ê¾å¤Î¿·À¸»ù¤ò½ÐÀ¸¸å1Æü¡Á3Æü¤Î´Ö¤Ë¥·¥ó¥Ð¥¤¥ª¥Æ¥£¥Ã¥¯ÅêÍ¿¡Ê¿¢ÊªÀ­Æý»À¶Ý¤È¥Õ¥ë¥¯¥È¥ª¥ê¥´Åü¡Ë¤â¤·¤¯¤Ï¥×¥é¥»¥Ü¤È¤·¤Æ¥Ç¥­¥¹¥È¥í¡¼¥¹¿©±ö¿å¤Ë¡¢2ÂÐ¥1¤Î³ä¹ç¤Çʬ¤±¤Þ¤·¤¿¡£ÅêÍ¿´ü´Ö¤Ï7Æü´Ö¡¢Êظ¡ºº¤òºÇ½é¤ÎÆü¡¢3ÆüÌÜ¡¢7ÆüÌÜ¡¢14ÆüÌÜ¡¢21ÆüÌÜ¡¢28ÆüÌܤ˹Ԥä¿¡£


·ë²Ì

19¿Í¤Î¿·À¸»ù¤¬¥·¥ó¥Ð¥¤¥ª¥Æ¥£¥Ã¥¯½èÃÖ¤ò¼õ¤±¡¢12¿Í¤¬¥×¥é¥»¥Ü½èÃÖ¤ò7Æü´Ö¼õ¤±¤¿

¥·¥ó¥Ð¥¤¥ª¥Æ¥£¥Ã¥¯½èÃÖ¤ò¼õ¤±¤¿¿·À¸»ù9Êؤ«¤é¿¢ÊªÀ­Æý»À¶Ý¤¬3ÆüÌܤˤÏ84%¡¢28ÆüÌܤˤÏ95%¤¬¸¡½Ð¤µ¤ì¤¿¡£2¥ö·îÌܤˤÏ100%¡¢3¥ö·îÌܤˤÏ94¡ó¡¢4¥ö·îÌܤˤÏ88¡ó¡¢5¥ö·îÌܤˤÏ56%¡¢6¥ö·îÌܤˤÏ32%¡¢Êؤ«¤é¿¢ÊªÀ­Æý»À¶Ý¤¬¸¡½Ð¤µ¤ì¤¿¡£

¡Ê2012/7/30 ·ÇºÜ¡Ë

ǧÃξ㳲¤È¥¢¥ë¥Ä¥Ï¥¤¥Þ¡¼É¡¢»À²½Åª¥¹¥È¥ì¥¹¤È¥³¥ì¥¹¥Æ¥í¡¼¥ë¤Î´Ø·¸

ÏÀʸ¤Ç¾Ò²ð¤·¤Þ¤¹

Cognitive impairment and Alzheimer’s disease: Links with oxidative stress and cholesterol metabolism
ǧÃξ㳲¤È¥¢¥ë¥Ä¥Ï¥¤¥Þ¡¼É¡¡»À²½Åª¥¹¥È¥ì¥¹¤È¥³¥ì¥¹¥Æ¥í¡¼¥ëÂå¼Õ¤Î´Ø·¸
Alejandra Sekler¡¡Ç§ÃοÀ·Ð²Ê³Ø¥»¥ó¥¿¡¼¡¡¥Á¥ê
Beuropsychiatric Disease and Treatment 2008:4(4)715-722


¥¢¥ë¥Ä¥Ï¥¤¥Þ¡¼É¤Ϻ£ÆüºÇ¤â¿¤¤ÃÔÊò¤Ç¤¹¡£¥¢¥ë¥Ä¥Ï¥¤¥Þ¡¼É¤ÏǾ¤ÎÃæ¤Ë¥¿¥ó¥Ñ¥¯¤Î¶Å½¸ÂΤηÁÀ®¤¬ÆÃħŪ¤Ç¡¢¤½¤ì¤Ï²á¥ê¥ó»À²½¤µ¤ì¤¿¥¿¥¦¥¿¥ó¥Ñ¥¯¤ÈAβ¡Ê¥¨¡¼¥Ù¡¼¥¿¡¼¡Ë¥×¥é¡¼¥¯¤«¤é¤Ç¤­¤Æ¤¤¤ë¡£¥¢¥ë¥Ä¥Ï¥¤¥Þ¡¼É¤ä¾¤Î¿À·ÐÊÑÀ­É¤ÎÉ°ø¤Ï¡¢»À²½Åª¥¹¥È¥ì¥¹¤Ç¤¢¤ê¡¢·ë²Ì¤È¤·¤Æ¿À·ÐºÙ˦¤Îµ¡Ç½¾ã³²¤È¿À·ÐºÙ˦»à¤Ë¤Ä¤Ê¤¬¤Ã¤Æ¤¤¤Þ¤¹¡£»À²½Åª¥¹¥È¥ì¥¹¤Ï¡¢³èÀ­»ÀÁǼï¤äÃâÁǼï¤ÎÄ´Àá¤Ç¤­¤Ê¤¤À¸»º¤Î·ë²Ì¤Ç¡¢¥¿¥ó¥Ñ¥¯¼Á¡¢»é¼Á¡¢³Ë»À¤Î¹½Â¤ÊѲ½¤ò¾·¤¤¤Æ¤¤¤Þ¤¹¡£

¤³¤ì¤é¤Î¤³¤È¤«¤é¡¢¥¢¥ë¥Ä¥Ï¥¤¥Þ¡¼¤Î¸¶°ø¤È¤·¤Æ¡¢»À²½¾ã³²¤Ç¤¢¤ë¤È¤¤¤¦¤¤¤¯¤Ä¤«¤Î²¾À⤬½Ð¤µ¤ì¤Æ¤¤¤Þ¤¹¡£ÃÔÊò¤ä¾¤Î¿À·ÐÊÑÀ­É¤οʹԤȻÀ²½Åª¥¹¥È¥ì¥¹¤Î»Øɸ¤Î´Ø·¸¤ò¼¨¤·¤Æ¤¤¤ë¸¦µæ¤¬¤¢¤ê¤Þ¤¹¡£

¤µ¤é¤Ë¡¢¥¢¥ë¥Ä¥Ï¥¤¥Þ¡¼É¤οʹԤȡ¢¥³¥ì¥¹¥Æ¥í¡¼¥ë¤È¤Î´Ø·¸¤ò¼¨¤¹¾Úµò¤¬¤¢¤ê¤Þ¤¹¡£¹â¥³¥ì¥¹¥Æ¥í¡¼¥ë·ì¾É¤Ï¡¢¥¢¥ß¥í¥¤¥É¤Î¡ÊǾ¤ËÃßÀѤ¹¤ëAβ¡Ë¿Ê¹Ô¤Î½é´ü¤Î¥ê¥¹¥¯¥Õ¥¡¥¯¥¿¡¼¤Ç¤¢¤ê¡¢Ä¹´ü´Ö¤Î½¸ÃĤòÄÉÀפ·¤¿¸¦µæ¤Ï¥³¥ì¥¹¥Æ¥í¡¼¥ë¤¬ÈÕǯ¤Î¥¢¥ë¥Ä¥Ï¥¤¥Þ¡¼É¤˴ط¸¤·¤Æ¤¤¤ë¤³¤È¤ò¾ÚÌÀ¤·¤Æ¤¤¤Þ¤¹¡£

¥¢¥Ý§¦¥¿¥ó¥Ñ¥¯¤Ï¥³¥ì¥¹¥Æ¥í¡¼¥ë¤ä¾¤Î»éËäηìή¤äǾÀÔ¿ñ±Õ¤Ç¤ÎÍ¢Á÷¤ò¤·¤Æ¤¤¤Þ¤¹¡£

¥¢¥ÝE¥¿¥ó¥Ñ¥¯¤Ë¤Ï3¤Ä¤Î°äÅÁ»Ò·¿ε2¡¢ε3¡¢ε4¤¬¤¢¤ê¡¢ε4¤ò¥Û¥â¤Ë»ý¤Ä¡Êξ¿Æ¤«¤é¤¤¤º¤ì¤âε4¤ò¼õ¤±·Ñ¤¤¤Ç¤¤¤ë¾ì¹ç¡Ë¤Ï¡¢¥¢¥ë¥Ä¥Ï¥¤¥Þ¡¼É¤Υꥹ¥¯¤¬¹â¤¤¡£¥¢¥ë¥Ä¥Ï¥¤¥Þ¡¼É¤δµ¼Ô¤ÎǾÃæ¤Î²á»À²½¥ì¥Ù¥ë¤Ï¥¢¥ÝE¤Î°äÅÁ»Ò·¿¤Ë¤è¤Ã¤Æ¤ª¤ê¡¢ε4¤Î¾ì¹ç¡¢¹â¤¤¤³¤È¤¬Ê¬¤«¤Ã¤Æ¤¤¤Þ¤¹¡£¡Ê¥¢¥ÝE¤ÎÍͤʡ˻é¼Á¤òÍ¢Á÷¤¹¤ë¥¿¥ó¥Ñ¥¯¤Ï¡¢³èÀ­»ÀÁǤÎɸŪ¤Ç¤¢¤ê¡¢¥¢¥ÝE¡¦¥¿¥ó¥Ñ¥¯¤Î²á»À²½¤È¥¢¥ë¥Ä¥Ï¥¤¥Þ¡¼É¤ˤϴØÏ¢¤¬¤¢¤ê¤Þ¤¹¡£°ÊÁ°¤Î´µ¼Ô¤Î¸¦µæ¤Ç¡¢»À²½Åª¥¹¥È¥ì¥¹¤Ï¤Ï¤Ã¤­¤ê¤È¡¢Ç§ÃΤÎÄã²¼¤Ë·ë¤Ó¤Ä¤¤¤Æ¤ª¤ê¡¢¥¢¥ë¥Ä¥Ï¥¤¥Þ¡¼É¤δµ¼Ô¤Î»À²½¥Ð¥é¥ó¥¹¤Î°­¤µ¤Ï¡¢¤¤¤í¤¤¤í¤ÊÀ¸Êª»Øɸ¤«¤é¤Ï¤Ã¤­¤ê¤·¤Æ¤¤¤Þ¤¹¡£

¡Ê2012/07/30 ·ÇºÜ¡Ë

1

¿©ÉÊ°ÂÁ´¾ðÊ󸡺÷



̾¸Å²°À¸³è¥¯¥é¥Ö

  ¢©452-0802¡¡Ì¾¸Å²°»ÔÀ¾¶èÈæÎÉ2-120¡¡¥Õ¥ê¡¼¥À¥¤¥¢¥ë¡§0120-72-0251
TEL¡§052-501-0251¡¡FAX¡§052-503-0967 e-mail¡§ nsc@athena.ocn.ne.jp¡¡
>>²ñ¼Ò³µÍפϥ³¥Á¥é
  ¥¯¥ê¥Ã¥¯¤è¤¯¤¢¤ë¤´¼ÁÌä